S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Sell every Stock except ONE (Ad)
Russia accused of 'kidnapping' head of Ukraine nuclear plant
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
Sell every Stock except ONE (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
UK train strikes and energy hikes add to a week of turmoil
Sell every Stock except ONE (Ad)
NIH to fund unproven ALS drugs under patient-backed law
Russia blindfolds, detains Ukraine nuclear plant chief
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Sell every Stock except ONE (Ad)
Russia accused of 'kidnapping' head of Ukraine nuclear plant
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
Sell every Stock except ONE (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
UK train strikes and energy hikes add to a week of turmoil
Sell every Stock except ONE (Ad)
NIH to fund unproven ALS drugs under patient-backed law
Russia blindfolds, detains Ukraine nuclear plant chief
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Sell every Stock except ONE (Ad)
Russia accused of 'kidnapping' head of Ukraine nuclear plant
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
Sell every Stock except ONE (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
UK train strikes and energy hikes add to a week of turmoil
Sell every Stock except ONE (Ad)
NIH to fund unproven ALS drugs under patient-backed law
Russia blindfolds, detains Ukraine nuclear plant chief
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Sell every Stock except ONE (Ad)
Russia accused of 'kidnapping' head of Ukraine nuclear plant
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
Sell every Stock except ONE (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
UK train strikes and energy hikes add to a week of turmoil
Sell every Stock except ONE (Ad)
NIH to fund unproven ALS drugs under patient-backed law
Russia blindfolds, detains Ukraine nuclear plant chief
NYSEAMERICAN:ELMD

Electromed - ELMD Stock Forecast, Price & News

$10.25
-0.06 (-0.58%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$10.25
$11.15
50-Day Range
N/A
52-Week Range
$8.75
$13.46
Volume
18,371 shs
Average Volume
10,984 shs
Market Capitalization
$86.87 million
P/E Ratio
41.00
Dividend Yield
N/A
Price Target
$17.83

Electromed MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
74.0% Upside
$17.83 Price Target
Short Interest
Bearish
0.85% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.09mentions of Electromed in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
51.61%
From $0.31 to $0.47 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.46 out of 5 stars

ELMD stock logo

About Electromed (NYSEAMERICAN:ELMD) Stock

Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system; SmartVest SQL System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment; and SmartVest Connect, a wireless technology with personalized HFCWO therapy management portal for patients with compromised pulmonary function. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products primarily to home health care and institutional markets for patients with bronchiectasis, cystic fibrosis, and neuromuscular diseases. It markets its products primarily to physicians and health care providers, as well as directly to patients. The company was incorporated in 1992 and is headquartered in New Prague, Minnesota.

Receive ELMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Electromed and its competitors with MarketBeat's FREE daily newsletter.

ELMD Stock News Headlines

Frank Stella Enters The Metaverse - Benzinga
See More Headlines
Receive ELMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Electromed and its competitors with MarketBeat's FREE daily newsletter.

ELMD Company Calendar

Last Earnings
8/23/2022
Today
10/02/2022
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSEAMERICAN:ELMD
Previous Symbol
NYSEMKT:ELMD
Employees
132
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$17.83
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$13.50
Forecasted Upside/Downside
+74.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$2.36 million
Pretax Margin
8.06%

Debt

Sales & Book Value

Annual Sales
$35.76 million
Cash Flow
$0.27 per share
Book Value
$3.75 per share

Miscellaneous

Free Float
6,282,000
Market Cap
$86.87 million
Optionable
Not Optionable
Beta
0.65

Key Executives

  • Ms. Kathleen S. Skarvan (Age 66)
    CEO, Pres & Director
    Comp: $701.64k
  • Ms. Michelle C. Wirtz (Age 39)
    Interim CFO, Treasurer, Sec. & Corp. Controller
  • Ms. Diane M. Kaufman
    VP of HR
  • Mr. Christopher G. Holland (Age 53)
    Chief Commercial Officer
  • Mr. William J. George (Age 73)
    Sec.













ELMD Stock - Frequently Asked Questions

Should I buy or sell Electromed stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Electromed in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ELMD shares.
View ELMD analyst ratings
or view top-rated stocks.

What is Electromed's stock price forecast for 2022?

4 brokers have issued 12 month price objectives for Electromed's shares. Their ELMD share price forecasts range from $13.50 to $20.00. On average, they anticipate the company's stock price to reach $17.83 in the next year. This suggests a possible upside of 74.0% from the stock's current price.
View analysts price targets for ELMD
or view top-rated stocks among Wall Street analysts.

How have ELMD shares performed in 2022?

Electromed's stock was trading at $12.95 on January 1st, 2022. Since then, ELMD stock has decreased by 20.8% and is now trading at $10.25.
View the best growth stocks for 2022 here
.

Are investors shorting Electromed?

Electromed saw a increase in short interest in September. As of September 15th, there was short interest totaling 51,800 shares, an increase of 26.3% from the August 31st total of 41,000 shares. Based on an average daily volume of 11,300 shares, the days-to-cover ratio is presently 4.6 days. Approximately 0.9% of the shares of the stock are sold short.
View Electromed's Short Interest
.

How were Electromed's earnings last quarter?

Electromed, Inc. (NYSEAMERICAN:ELMD) released its earnings results on Tuesday, August, 23rd. The medical equipment provider reported $0.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.08 by $0.04. Electromed had a net margin of 6.00% and a trailing twelve-month return on equity of 6.94%.

What other stocks do shareholders of Electromed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Electromed investors own include AbbVie (ABBV), TransEnterix (TRXC), AT&T (T), ACADIA Pharmaceuticals (ACAD), CRISPR Therapeutics (CRSP), Enphase Energy (ENPH), Inseego (INSG), Novavax (NVAX), NVIDIA (NVDA) and Pfizer (PFE).

What is Electromed's stock symbol?

Electromed trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ELMD."

How do I buy shares of Electromed?

Shares of ELMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Electromed's stock price today?

One share of ELMD stock can currently be purchased for approximately $10.25.

How much money does Electromed make?

Electromed (NYSEAMERICAN:ELMD) has a market capitalization of $86.87 million and generates $35.76 million in revenue each year. The medical equipment provider earns $2.36 million in net income (profit) each year or $0.25 on an earnings per share basis.

How many employees does Electromed have?

The company employs 132 workers across the globe.

How can I contact Electromed?

Electromed's mailing address is 500 6th Ave NW, NEW PRAGUE, MN 56071-1134, United States. The official website for the company is smartvest.com. The medical equipment provider can be reached via phone at (952) 758-9299, via email at investorrelations@electromed.com, or via fax at 866-758-5077.

This page (NYSEAMERICAN:ELMD) was last updated on 10/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.